Oct 28 2022 This Week in Cardiology

ERASE AF follow-up, recreational drugs and AF, etripamil, misuse of science, and diabetes as a cardiovascular risk factor are the topics John Mandrola, MD, discusses in this week’s podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I. Follow-up on ERASE AF

II. Recreational Drugs

Four Commonly Abused Drugs Linked With Atrial Fibrillation

https://www.medscape.com/viewarticle/983052

III. Etripamil

RAPID: Positive Data for Etripamil Nasal Spray in Paroxysmal SVT

https://www.medscape.com/viewarticle/982787

- Milestone Pharmaceuticals Announces Positive Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia https://investors.milestonepharma.com/news-releases/news-release-details/milestone-pharmaceuticals-announces-positive-results-phase-3

IV. Misuse of Science

When Bad Actors Hijack Good Research

https://www.medscape.com/viewarticle/982936

- Level and Prevalence of Spin in Published Cardiovascular Randomized Clinical Trial Reports With Statistically Nonsignificant Primary Outcomes: A Systematic Review https://pubmed.ncbi.nlm.nih.gov/31050775/

V. Diabetes as a Risk Factor

Diabetes Becoming Less Potent Risk Factor for CVD Events

https://www.medscape.com/viewarticle/982801

- Trends in the Association Between Diabetes and Cardiovascular Events, 1994-2019 https://jamanetwork.com/journals/jama/fullarticle/2797494

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact

[email protected]